The April order rescheduling DEA-approved medications and state-licensed medical marijuana to Schedule III set off a scramble in the capital markets. Two questions sit at the center of it: Can plant-touching companies finally list on the major U.S. stock exchanges, and will banks finally open their doors to the industry? On the first question, the
In the summer of 2017, Phish lit up Madison Square Garden with a historic 13-night run. Your friends at Budding Trends believe the marijuana rescheduling decision calls for a rollout just as monumental, so we’ve created the Budding Trends Baker’s Dozen as a fitting homage.
Following the federal government’s move to reschedule medical marijuana from
This is the fourth of 13 posts describing the impacts of marijuana’s rescheduling. An homage to Phish’s historic run at Madison Square Garden in the Summer of 2017, Budding Trends Baker’s Dozen will address how rescheduling affects various areas of the law and our daily lives. Enjoy the run.
Rescheduling marijuana to Schedule III is
This is the second of 13 posts describing the impacts of marijuana’s rescheduling. An homage to Phish’s historic run at Madison Square Garden in the Summer of 2017, Budding Trends Baker’s Dozen will address how rescheduling affects various areas of the law and our daily lives. Enjoy the run.
These days nobody agrees on anything.
It’s not always bad news when cannabis operators interact with the federal government. After all, the federal government largely allows marijuana companies to operate in an overwhelming majority of states without federal interference even though marijuana is classified as a Schedule I substance under federal law.
But there does seem to be a common theme